Poinciana Advisors Group LLC Sells 2,557 Shares of Johnson & Johnson $JNJ

Key Points

• Poinciana Advisors Group LLC has reduced its stake in Johnson & Johnson by 23.6%, selling 2,557 shares and now holding 8,271 shares worth approximately $1,263,000.
• During the recent quarter, several hedge funds have increased their positions in Johnson & Johnson, with Brighton Jones LLC boosting its stake by 13.9% and Merit Financial Group LLC by 35.9%.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding analysts' expectations, and announced a quarterly dividend of $1.30, yielding 2.8% annually.

Poinciana Advisors Group LLC reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,271 shares of the company's stock after selling 2,557 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Poinciana Advisors Group LLC's holdings, making the stock its 19th largest position. Poinciana Advisors Group LLC's holdings in Johnson & Johnson were worth $1,263,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Merit Financial Group LLC boosted its position in shares of Johnson & Johnson by 35.9% in the 1st quarter. Merit Financial Group LLC now owns 137,423 shares of the company's stock worth $22,790,000 after purchasing an additional 36,312 shares in the last quarter. HBW Advisory Services LLC boosted its position in shares of Johnson & Johnson by 13.3% in the 1st quarter. HBW Advisory Services LLC now owns 7,401 shares of the company's stock worth $1,227,000 after purchasing an additional 867 shares in the last quarter. InvesTrust boosted its position in shares of Johnson & Johnson by 1.6% in the 1st quarter. InvesTrust now owns 44,791 shares of the company's stock worth $7,428,000 after purchasing an additional 689 shares in the last quarter. Finally, RFG Advisory LLC raised its holdings in Johnson & Johnson by 9.0% in the 1st quarter. RFG Advisory LLC now owns 18,278 shares of the company's stock worth $3,031,000 after acquiring an additional 1,515 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $185.40 on Wednesday. The firm has a market cap of $446.51 billion, a PE ratio of 19.83, a P/E/G ratio of 2.31 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $175.11 and a two-hundred day simple moving average of $162.34. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $185.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Bank of America boosted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Citigroup boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $181.40.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.